Stockscreener 앱 받기
0.23
6.20%
-0.0152
시간 외 거래:
.24
0.010
+4.35%
전일 마감가:
$0.2452
열려 있는:
$0.24
하루 거래량:
139.37K
Relative Volume:
0.07
시가총액:
$47.35M
수익:
$74,000
순이익/손실:
$-13.43M
주가수익비율:
-0.0245
EPS:
-9.4
순현금흐름:
$-10.54M
1주 성능:
-24.79%
1개월 성능:
-28.66%
6개월 성능:
-75.00%
1년 성능:
-89.50%
1일 변동 폭
$0.23
$0.25
1주일 범위
$0.2215
$0.307
52주 변동 폭
$0.2215
$4.00
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
명칭
Cyclacel Pharmaceuticals Inc
전화
908-517-7330
주소
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
CYCC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
0.23 | 47.35M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2020-04-27 | 재개 | ROTH Capital | Buy |
| 2018-09-07 | 개시 | Ladenburg Thalmann | Buy |
| 2015-10-16 | 개시 | H.C. Wainwright | Buy |
| 2010-02-04 | 개시 | Roth Capital | Buy |
| 2009-10-28 | 개시 | Merriman | Buy |
| 2008-08-12 | 개시 | Piper Jaffray | Buy |
| 2008-03-12 | 재확인 | Cantor Fitzgerald | Buy |
| 2008-03-12 | 재확인 | Collins Stewart | Buy |
| 2008-03-12 | 재확인 | Needham & Co | Buy |
| 2007-11-27 | 재확인 | Cantor Fitzgerald | Buy |
| 2007-08-10 | 재확인 | Cantor Fitzgerald | Buy |
| 2007-06-04 | 재확인 | Needham & Co | Buy |
| 2007-04-23 | 개시 | Lazard Capital | Buy |
| 2007-04-10 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Cyclacel Pharmaceuticals Inc 주식(CYCC)의 최신 뉴스
Cyclacel Pharmaceuticals Shifts Focus to Cancer Drug Development - TipRanks
Cyclacel Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Cyclacel Pharmaceuticals Appoints New Directors Amid Strategic Shift - TipRanks
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results And Provides Business Update - MarketScreener
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update - The Manila Times
Cyclacel Slashes Net Loss in Half, Streamlines to Focus on Promising Cancer Drug - Stock Titan
Cyclacel Pharmaceuticals Delays 10-K Filing - TipRanks
CYCC stock touches 52-week low at $0.29 amid sharp annual decline By Investing.com - Investing.com South Africa
CYCC stock touches 52-week low at $0.29 amid sharp annual decline - Investing.com
StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Financial Contrast: Cellectar Biosciences (NASDAQ:CLRB) versus Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cyclacel Pharmaceuticals to offer convertible preferred stock in private placement - MSN
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering Of Convertible Preferred Stock - Marketscreener.com
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock - The Manila Times
Cyclacel's Latest $1M Financing Deal Reveals Extended Survival Strategy Through Q3 2025 - Stock Titan
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com - Defense World
Cyclacel Pharmaceuticals’ Change of Control Transaction and Appointment of New Executive Leadership - Global Legal Chronicle
(CYCCP) Trading Advice - news.stocktradersdaily.com
Cyclacel Pharmaceuticals (CYCC) Projected to Post Earnings on Tuesday - The AM Reporter
CYCLACEL PHARMACEUTICALS Earnings Preview: Recent $CYCC Insider Trading, Hedge Fund Activity, and More - Nasdaq
StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cyclacel Pharmaceuticals acquires cancer drug assets By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals acquires cancer drug assets - Investing.com
Cyclacel stock plunges to 52-week low at $0.3 amid market challenges - Investing.com Australia
Cyclacel stock plunges to 52-week low at $0.3 amid market challenges By Investing.com - Investing.com South Africa
Cyclacel Pharmaceuticals (CYCC) to Release Earnings on Tuesday - Defense World
Cyclacel stock plunges to 52-week low of $0.31 amid market challenges - MSN
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com - Defense World
Cyclacel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Cyclacel Pharmaceuticals interim CEO David Lazar sells $5.5 million in stock - Investing.com India
Cyclacel Pharmaceuticals Announces New Leadership and Restructuring - TipRanks
Cyclacel Pharmaceuticals Says Datuk Dr.Doris Wong Sing Ee Elected As CEO & Executive Director - Marketscreener.com
Cyclacel Pharmaceuticals Expands Executive Leadership Team - citybiz
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership - The Manila Times
Investor Network: Cyclacel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Who Now Controls Cyclacel? New Investor Takes 70% Ownership in $6.3M Leadership Overhaul - StockTitan
Buffett’s on the Sidelines – Should You Follow? - The Globe and Mail
Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, on Innovative Targeted Therapies for Advanced - DocWire News
Cyclacel Pharmaceuticals amends agreement with CEO By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals amends agreement with CEO - Investing.com
(CYCCP) Trading Report - news.stocktradersdaily.com
Head-To-Head Review: Cyclacel Pharmaceuticals (NASDAQ:CYCC) vs. Silence Therapeutics (NASDAQ:SLN) - Defense World
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $25 million in funding from Helena Special Opportunities LLC - Marketscreener.com
Cyclacel Pharmaceuticals streamlines operations, plans asset purchase - MSN
Cyclacel Pharmaceuticals Inc (CYCC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):